- Home
- ZEPP vs CBIO Comparison
ZEPP vs CBIO Comparison
Compare ZEPP & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZEPP | CBIO |
|---|---|---|
| Founded | 2013 | 2003 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 327.7M | 389.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ZEPP | CBIO |
|---|---|---|
| Price | $16.86 | $9.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $27.17 |
| AVG Volume (30 Days) | 132.4K | ★ 174.3K |
| Earning Date | 11-04-2025 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $233,274,000.00 | N/A |
| Revenue This Year | $887.39 | N/A |
| Revenue Next Year | $26.12 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.64 | N/A |
| 52 Week Low | $2.13 | $9.10 |
| 52 Week High | $61.85 | $21.40 |
Technical Indicators
Market Signals| Indicator | ZEPP | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 27.66 | 34.19 |
| Support Level | $15.37 | $9.10 |
| Resistance Level | $24.80 | $14.71 |
| Average True Range (ATR) | 1.84 | 1.14 |
| MACD | -0.49 | -0.29 |
| Stochastic Oscillator | 17.39 | 11.05 |
Price Performance
Historical ComparisonAbout ZEPP Zepp Health Corporation
Zepp Health Corp is engaged in the business of manufacturing smart health wearable products. The company operates in one segment which is Amazfit-branded products. The product portfolio includes smartwatches and fitness bands.
About CBIO Crescent Biopharma Inc.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.